Cargando…
Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections
MV130 is an inactivated polybacterial mucosal vaccine that confers protection to patients against recurrent respiratory infections, including those of viral etiology. However, its mechanism of action remains poorly understood. Here, we find that intranasal prophylaxis with MV130 modulates the lung i...
Autores principales: | Brandi, Paola, Conejero, Laura, Cueto, Francisco J., Martínez-Cano, Sarai, Dunphy, Gillian, Gómez, Manuel J., Relaño, Carlos, Saz-Leal, Paula, Enamorado, Michel, Quintas, Ana, Dopazo, Ana, Amores-Iniesta, Joaquín, del Fresno, Carlos, Nistal-Villán, Estanislao, Ardavín, Carlos, Nieto, Antonio, Casanovas, Miguel, Subiza, José Luis, Sancho, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cell Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755442/ https://www.ncbi.nlm.nih.gov/pubmed/34986349 http://dx.doi.org/10.1016/j.celrep.2021.110184 |
Ejemplares similares
-
The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity
por: del Fresno, Carlos, et al.
Publicado: (2021) -
Bacterial Mucosal Immunotherapy with MV130 Prevents Recurrent Wheezing in Children: A Randomized, Double-Blind, Placebo-controlled Clinical Trial
por: Nieto, Antonio, et al.
Publicado: (2021) -
Human dendritic cells activated with MV130 induce Th1, Th17 and IL‐10 responses via RIPK2 and MyD88 signalling pathways
por: Cirauqui, Cristina, et al.
Publicado: (2017) -
MV140 mucosal bacterial vaccine improves uropathogenic E. coli clearance in an experimental model of urinary tract infection
por: Saz-Leal, Paula, et al.
Publicado: (2023) -
Engineering Non-Human RNA Viruses for Cancer Therapy
por: Tur-Planells, Vicent, et al.
Publicado: (2023)